Revolutionary New Radiotherapy Slashes Prostate Cancer Treatment Sessions from 20 to 5!

Thousands of men in England with prostate cancer are set to benefit from a groundbreaking treatment that will dramatically reduce their radiotherapy sessions from the usual 20 down to just five. This new approach, known as SABR (stereotactic ablative radiotherapy), is poised to deliver a more focused and effective attack on the cancer, while also minimizing the side effects that often come with traditional radiotherapy.

This is the first time that this advanced technique will be made available to low- and intermediate-risk prostate cancer patients outside of clinical trials. Each year, around 55,000 men in the UK are diagnosed with prostate cancer, with about 17,500 classified as low or intermediate risk. Experts predict that approximately 3,500 of these men might opt for this innovative treatment, particularly since many low-risk patients choose active monitoring instead of immediate intervention due to the typically slow-growing nature of their cancers.

NHS England has announced that all 48 radiotherapy centers across the country are expected to start offering this treatment “within weeks,” which is great news for those affected. Professor Peter Johnson, the national clinical director for cancer, underlined the significance of this advancement, stating that it allows for a highly concentrated beam of radiotherapy to be aimed directly at the cancer, thus limiting damage to surrounding healthy cells. He emphasized that undergoing this treatment in just five sessions, rather than the usual 20, means men can get back to their normal lives much more quickly.

Amy Rylance from Prostate Cancer UK expressed her enthusiasm, calling it “wonderful news” that thousands of men will now have access to this revolutionary targeted therapy. She highlighted that this could significantly ease the burdens faced by these men and their families. The charity is also hopeful that further advancements will allow even more prostate cancer patients to benefit from this treatment.

Trials are already in progress to investigate whether this precision radiotherapy can also be extended to high-risk prostate cancer patients. Edwin Lambert, a 70-year-old man from Suffolk, is participating in one of these trials. Diagnosed with prostate cancer in January 2025, he began hormone therapy but faced challenging side effects, including mood swings and fatigue. After receiving SABR, he reported that the treatment was “easier to deal with” compared to traditional options. While undergoing treatment, he observed other patients receiving standard radiotherapy who looked “dreadful” due to repeated sessions. Edwin experienced some discomfort, such as frequent urination during and shortly after his sessions, but was back to his archaeological dig within five weeks, describing the treatment as an “absolute godsend.”

In related news, a local charity event called Dorset’s Distinguished Gentleman’s Ride has raised more funds for cancer than any other event in Europe. Kevin Webber, who has been fundraising since his diagnosis in 2014, has clocked over 20,000 miles in support of cancer research. Meanwhile, health experts are still evaluating the best ways to screen for prostate cancer, as blood tests alone lack the necessary accuracy for many men.

With the ongoing developments in prostate cancer treatment, it’s clear that hope is on the horizon for many. As the healthcare community continues to explore new avenues, one can’t help but wonder what other breakthroughs are yet to come…

Kaynak: Orijinal Haber